Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers

Abstract

ObjectiveTo identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs).MethodsUsing pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health‐related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks’ treatment.ResultsProportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D). Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D). In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg. Greater improvements in cardiometabolic risk factors and health‐related quality of life scores were observed in ERs versus ENRs.ConclusionsThe early response criterion was clinically useful to identify individuals who would achieve clinically meaningful weight loss at 56 weeks.

Early weight loss predicts weight loss treatment response regardless of binge‐eating disorder status and pretreatment weight change

“…While the average weight loss was relatively small, effect sizes for both intervention conditions were medium to medium‐large and there was much variability, with approximately 25% of participants receiving treatment reaching a clinically meaningful weight loss of 5% or more by 3‐month follow‐up (Barnes et al, ). The current data support previously published trials examining Early Weight Loss (Carels et al, ; Feig & Lowe, ; Fujioka et al, ; Nackers et al, ; Unick et al, ; Waring et al, ) and extend them to individuals diagnosed with BED. The findings maintained through post‐treatment regardless of how weight loss outcomes were calculated.…”

“…"Early Weight Loss," or participants' initial weight loss in treatment, may be predictive of weight loss treatment outcomes (Carels, Cacciapaglia, Douglass, Rydin, & O'Brien, 2003;Nackers, Ross, & Perri, 2010) as far as one (Fujioka et al, 2016;Waring et al, 2014) to two (Feig & Lowe, 2017) years and up to four and eight years (Unick et al, 2015) following treatment. Studies of early weight loss suggest that participants who lose more weight initially during treatment will continue to lose significantly more weight compared with individuals who do not.…”

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

“…In SCALE IBT, 78.7% of participants treated with liraglutide‐IBT met the US label stopping rule of ≥ 4% weight loss by week 16, and of these individuals, almost three‐quarters (72.2%) achieved ≥ 5% weight loss at week 56. These numbers are similar to those observed in SCALE Obesity and Prediabetes, in which 77.3% of individuals treated with liraglutide 3.0 mg, as an adjunct to “standard” diet and exercise recommendations, met the week 16 ≥ 4% weight‐loss criterion . Fully 84.1% of these qualifying individuals went on to achieve ≥ 5% weight loss at week 56 .…”

Preoperative weight loss with glucagon‐like peptide‐1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis

“…We hypothesized that greater weight change achieved by GLP‐1 receptor agonist (GLP‐1RA) treatment before surgery would predict greater post‐surgical weight loss and greater weight loss from the start of MWM to 12 months post‐surgery. The observation that the amount of weight loss within 16 weeks of starting a GLP‐1RA predicts weight loss at 1 year of treatment with GLP‐1RA further supports the hypothesis that initial response to GLP‐1RA treatment may be a good predictor of long‐term weight loss …”

“…1,2 Gut hormones, such as peptide YY and glucagon-like peptide-1 further supports the hypothesis that initial response to GLP-1RA treatment may be a good predictor of long-term weight loss. 7 In the present study, our primary aim was to assess the relationship between preoperative GLP-1RA-induced weight changes and the weight change achieved from the start of MWM until 12 months post-bariatric surgery (total weight change [TWC]). A secondary aim was to assess the relationship between weight changes after preoperative GLP-1RA treatment and surgically induced weight changes at 12 months after bariatric surgery.…”